Robert F Storey

Summary

Affiliation: University of Sheffield
Country: UK

Publications

  1. ncbi request reprint Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin
    Robert F Storey
    Cardiovascular Medicine, University Hospital, Queen s Medical Centre, Nottingham, UK
    Thromb Haemost 88:488-94. 2002
  2. doi request reprint Platelet function testing and prediction of procedural bleeding risk
    E L Grove
    Department of Cardiovascular Science, University of Sheffield, Beech Hill Road, Sheffield, UK
    Thromb Haemost 109:817-24. 2013
  3. doi request reprint Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy)
    Robert F Storey
    Department of Cardiovascular Science, University of Sheffield, United Kingdom
    Am J Cardiol 108:1542-6. 2011
  4. doi request reprint Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes
    Robert F Storey
    Department of Cardiovascular Science, University of Sheffield, UK
    Eur Heart J 32:2945-53. 2011
  5. ncbi request reprint Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3
    Robert F Storey
    Cardiovascular Research Unit, University of Sheffield, Sheffield, UK
    Platelets 20:341-8. 2009
  6. doi request reprint Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study
    Robert F Storey
    Department of Cardiovascular Science, University of Sheffield, and NIHR Cardiovascular Biomedical Research Unit, Sheffield, United Kingdom
    J Am Coll Cardiol 56:185-93. 2010
  7. doi request reprint Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy
    Robert F Storey
    Department of Cardiovascular Science, University of Sheffield, and NIHR Cardiovascular Biomedical Research Unit, Sheffield, United Kingdom
    J Am Coll Cardiol 56:1456-62. 2010
  8. doi request reprint Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors
    Robert F Storey
    Department of Cardiovascular Science, University of Sheffield, Beech Hill Road, Sheffield, UK
    Thromb Haemost 105:S75-81. 2011
  9. doi request reprint Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses
    R F Storey
    NIHR Cardiovascular Biomedical Research Unit and Department of Cardiovascular Science, University of Sheffield, Sheffield, UK
    J Thromb Haemost 9:1730-7. 2011
  10. ncbi request reprint Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes
    Robert F Storey
    Cardiovascular Research Unit, University of Sheffield, Sheffield, United Kingdom
    J Am Coll Cardiol 50:1852-6. 2007

Collaborators

Detail Information

Publications30

  1. ncbi request reprint Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin
    Robert F Storey
    Cardiovascular Medicine, University Hospital, Queen s Medical Centre, Nottingham, UK
    Thromb Haemost 88:488-94. 2002
    ..These effects of clopidogrel and AR-C69931MX may confer therapeutic benefits in the management of acute coronary syndromes...
  2. doi request reprint Platelet function testing and prediction of procedural bleeding risk
    E L Grove
    Department of Cardiovascular Science, University of Sheffield, Beech Hill Road, Sheffield, UK
    Thromb Haemost 109:817-24. 2013
    ..Further large studies are needed to guide best practice in the application of platelet function testing in the clinical management of patients treated with antiplatelet drugs in order to optimise individual care...
  3. doi request reprint Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy)
    Robert F Storey
    Department of Cardiovascular Science, University of Sheffield, United Kingdom
    Am J Cardiol 108:1542-6. 2011
    ..In conclusion, no effect of ticagrelor on pulmonary function was seen in this cohort of patients with acute coronary syndromes compared to clopidogrel...
  4. doi request reprint Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes
    Robert F Storey
    Department of Cardiovascular Science, University of Sheffield, UK
    Eur Heart J 32:2945-53. 2011
    ....
  5. ncbi request reprint Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3
    Robert F Storey
    Cardiovascular Research Unit, University of Sheffield, Sheffield, UK
    Platelets 20:341-8. 2009
    ..Seventy four SNPs within three genes were genotyped. After adjustment for multiple comparisons, none of these SNPs were found to significantly influence inhibition of ADP-induced platelet aggregation by ticagrelor...
  6. doi request reprint Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study
    Robert F Storey
    Department of Cardiovascular Science, University of Sheffield, and NIHR Cardiovascular Biomedical Research Unit, Sheffield, United Kingdom
    J Am Coll Cardiol 56:185-93. 2010
    ....
  7. doi request reprint Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy
    Robert F Storey
    Department of Cardiovascular Science, University of Sheffield, and NIHR Cardiovascular Biomedical Research Unit, Sheffield, United Kingdom
    J Am Coll Cardiol 56:1456-62. 2010
    ..The PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy aimed to compare the antiplatelet effects of clopidogrel and ticagrelor in patients with acute coronary syndromes...
  8. doi request reprint Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors
    Robert F Storey
    Department of Cardiovascular Science, University of Sheffield, Beech Hill Road, Sheffield, UK
    Thromb Haemost 105:S75-81. 2011
    ..The pharmacology and clinical trial data for each of these inhibitors are discussed and compared with relevant data for the thienopyridines clopidogrel and prasugrel...
  9. doi request reprint Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses
    R F Storey
    NIHR Cardiovascular Biomedical Research Unit and Department of Cardiovascular Science, University of Sheffield, Sheffield, UK
    J Thromb Haemost 9:1730-7. 2011
    ..P2Y(12) inhibition increases the bleeding risk in patients requiring surgery...
  10. ncbi request reprint Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes
    Robert F Storey
    Cardiovascular Research Unit, University of Sheffield, Sheffield, United Kingdom
    J Am Coll Cardiol 50:1852-6. 2007
    ..clopidogRel in non-ST-segment Elevation myocardial infarction)-2, we compared the antiplatelet effects of AZD6140 and clopidogrel and assessed the effects of AZD6140 in clopidogrel-pretreated patients...
  11. ncbi request reprint Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin
    Robert F Storey
    Cardiovascular Research Unit, Clinical Sciences Centre, Northern General Hospital, Sheffield S5 7AU, UK
    Thromb Res 115:301-7. 2005
    ..We assessed the ability of cangrelor, a selective P2Y12 antagonist, A2P5P, a selective P2Y1 antagonist, and aspirin to block the potentiating effects of heparin...
  12. ncbi request reprint Biology and pharmacology of the platelet P2Y12 receptor
    Robert F Storey
    Cardiovascular Research Unit, Clinical Sciences Centre, University of Sheffield, Northern General Hospital, Herries Road, Sheffield, S5 7AU, UK
    Curr Pharm Des 12:1255-9. 2006
    ..However, current therapeutic regimens of clopidogrel yield variable and incomplete P2Y(12) receptor blockade and more effective strategies to block P2Y(12) receptor activation offer the potential of greater clinical efficacy...
  13. ncbi request reprint Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease
    Robert F Storey
    Cardiovascular Medicine, University Hospital, Queen s Medical Centre, Nottingham, NG7 2UH, UK
    Platelets 13:407-13. 2002
    ..In conclusion, therapeutic administration of clopidogrel moderately inhibits platelet P2Y(12) receptor activation and substantially greater P2Y(12) receptor blockade can be achieved with AR-C69931MX...
  14. doi request reprint Hirudin anticoagulation allows more rapid determination of P2Y₁₂ inhibition by the VerifyNow P2Y12 assay
    Wael Sumaya
    Department of Cardiovascular Science, University of Sheffield, Centre for Biomedical Research, Northern General Hospital, Herries Road, Sheffield, S5 7AU, UK
    Thromb Haemost 109:550-5. 2013
    ..Further studies are warranted to assess the utility of this method for improving clinical outcomes in patients undergoing PCI...
  15. ncbi request reprint Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function
    Heather M Judge
    Cardiovascular Science, School of Medicine and Biomedical Sciences, University of Sheffield, Royal Hallamshire Hospital, Sheffield, UK
    Thromb Haemost 103:1210-7. 2010
    ..These data guide the interpretation of results from different assays used to monitor the effects of P2Y12 receptor antagonists...
  16. doi request reprint The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses
    Heather M Judge
    University of Sheffield, Sheffield, UK
    Platelets 19:125-33. 2008
    ..Prasugrel's active metabolite effectively blocks the P2Y(12) receptor with the highest concentrations tested yielding complete inhibition of P2Y(12)-mediated amplification of several important platelet responses...
  17. ncbi request reprint Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy
    Simon M G Smith
    Cardiovascular Research Unit, University of Sheffield, Division of Clinical Sciences North, Northern General Hospital, Sheffield, UK
    Platelets 17:250-8. 2006
    ..In conclusion, common sequence variations within the P2Y12 and CYP3A5 genes do not contribute any major effect to the inter-patient variability in clopidogrel efficacy...
  18. ncbi request reprint Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses
    Heather M Judge
    Cardiovascular Research Unit, Clinical Sciences Centre, Northern General Hospital, Sheffield S5 7AU, UK
    Platelets 16:398-407. 2005
    ..These interactions are likely to have important influences on the safety and efficacy of combination anti-platelet therapies...
  19. doi request reprint Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima
    Shankar B Patil
    Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom
    Arterioscler Thromb Vasc Biol 30:2385-91. 2010
    ..Our goal was to study the effects of ticagrelor on murine platelet function and thrombosis and characterize the time course of P2Y(12) inhibition required to inhibit neointima formation following vascular injury...
  20. ncbi request reprint Development and clinical use of prasugrel and ticagrelor
    Shiraz Ahmad
    Department of Cardiovascular Science, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK
    Curr Pharm Des 18:5240-60. 2012
    ..Here, we examine the rationale for the development and clinical integration of antiplatelet agents focusing upon prasugrel and ticagrelor...
  21. doi request reprint Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting
    Javaid Iqbal
    Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom
    EuroIntervention 9:62-9. 2013
    ..We aimed to examine the incidence of ST and associated risk factors in this "real-world, all-comers" study...
  22. ncbi request reprint Utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients with acute coronary syndromes scheduled for coronary intervention
    Anjan Siotia
    Cardiovascular Research Unit, University of Sheffield, Clinical Sciences Centre, Northern General Hospital, Sheffield, United Kingdom
    Thromb Haemost 95:997-1002. 2006
    ..A WBSPC assay of platelet microaggregation shows promise for monitoring GPIIb/IIIa antagonists...
  23. ncbi request reprint Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention
    Simon M G Smith
    Cardiovascular Research Group, University of Sheffield, Clinical Sciences Centre, Northern General Hospital, Sheffield, UK
    Platelets 15:465-74. 2004
    ....
  24. doi request reprint Contemporary management of ST-segment elevation myocardial infarction
    Arun Karunakaran
    Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom
    Hosp Pract (1995) 40:224-31. 2012
    ..In this article, we aim to provide a summary of a few key advances in the management of ST-segment elevation myocardial infarction...
  25. ncbi request reprint Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor
    Jon R Ward
    Section of Functional Genomics, University of Sheffield, UK
    Thromb Haemost 94:831-8. 2005
    ....
  26. ncbi request reprint Vessel wall, not platelet, P2Y12 potentiates early atherogenesis
    Laura E West
    Department of Cardiovascular Science, University of Sheffield, Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Cardiovasc Res 102:429-35. 2014
    ..We therefore examined the role of platelet vs. vessel wall P2Y12 in early atherogenesis and considered the use of P2Y12 antagonists ticagrelor and clopidogrel in modulating this process...
  27. ncbi request reprint Clopidogrel resistance
    Stan Heptinstall
    Catheter Cardiovasc Interv 63:397-8. 2004
  28. ncbi request reprint Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
    Christopher P Cannon
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 50:1844-51. 2007
    ..Our goal was to compare the safety and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, with clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)...
  29. ncbi request reprint Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes
    Miles W H Behan
    Division of Cardiovascular Medicine, Queens Medical Centre, Nottingham NG7 2UH, UK
    Platelets 16:73-80. 2005
    ..The results provide new information on the mechanisms involved in the beneficial effects of P2Y(12) antagonists in patients with ACS...
  30. ncbi request reprint Platelets: developmental biology, physiology, and translatable platforms for preclinical investigation and drug development
    Neal S Kleiman
    Methodist DeBakey Heart Center, Houston, Texas, USA
    Platelets 19:239-51. 2008
    ....